Ex-Allergan VP joins Exscientia as chairman

29 September 2020

David Nicholson, the former executive vice president and chief R&D officer at Allergan, has been named chairman of the board of directors at UK-based Exscientia.

Dr Nicholson is joining a company that calls itself the world-leading artificial intelligence drug discovery company to help define and oversee the strategy and progression of its business model and discovery pipeline through to a clinical setting.

He has held a number of senior leadership positions over a 40-year career in research and development not just at Allergan, which has now been taken over by US drugmaker AbbVie (NYSE: ABBV), but also by Bayer (BAYN: DE), Merck & Co (NYSE: MRK), Schering-Plough and Organon.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK